Agilent Technologies
A
$148.44
-0.01%
Agilent Technologies Inc. is a global leader in life sciences, diagnostics, and applied chemical analysis, providing analytical instruments, software, consumables, and services to customers in biopharmaceutical, clinical, environmental, and academic markets. Spun out of Hewlett-Packard in 1999, the company operates through three segments—Life Sciences and Applied Markets, Agilent CrossLab, and Applied Markets—and is recognized for its precision measurement technologies and strong brand in the scientific community. The current investor narrative centers on Agilent's robust recovery and growth acceleration, driven by strong demand in its biopharmaceutical end markets, successful product innovations, and strategic acquisitions like Biocare Medical to expand in high-margin pathology. Recent quarterly results beat expectations, leading to a raised full-year profit forecast and a surge in the stock price, while the company navigates a dynamic macroeconomic environment with a focus on operational efficiency and margin expansion.…
A
Agilent Technologies
$148.44
Related headlines
Investment Opinion: Should I buy A Today?
Recommendation: Buy. Agilent's strong revenue acceleration, margin expansion, and positive analyst sentiment support a bullish stance. The average analyst target of $160.11 implies a 7.8% upside, and the consensus rating is 'Buy' (1.67 on a 1-5 scale). The company's ability to beat expectations and raise guidance underscores its operational strength.
Sign up to view all
A 12-Month Price Forecast
Agilent's forward-looking view is bullish, driven by accelerating revenue growth, margin expansion, and positive analyst sentiment. However, the elevated valuation and high beta warrant caution. The stance would be upgraded to 'high confidence' if the company delivers another quarter of double-digit growth and maintains margins. Conversely, a downgrade to 'neutral' would occur if growth decelerates below 8% or if the stock fails to hold above $140 support.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Agilent Technologies's 12-month outlook, with a consensus price target around $160.11 and implied upside of +7.9% versus the current price.
Average Target
$160.11
0 analysts
Implied Upside
+7.9%
vs. current price
Analyst Count
—
covering this stock
Price Range
$135 - $185
Analyst target range
The target price range is $135.00 (low) to $185.00 (high), with a spread of $50, or 33.6% of the average target, indicating moderate uncertainty. The high target of $185 implies a 24.6% upside, likely assuming continued strong execution, margin expansion, and successful integration of Biocare Medical, which could drive multiple expansion. The low target of $135 suggests a downside of -9.1%, possibly pricing in risks such as slower biopharma spending, competitive pressures, or macroeconomic headwinds. The wide range reflects divergent views on the sustainability of growth, but the overall bullish tilt suggests analysts see more upside than downside. Institutional ratings data shows recent upgrades and reaffirmations, with no downgrades in the last three months, reinforcing the positive outlook.
Bulls vs Bears: A Investment Factors
Agilent presents a compelling growth story with accelerating revenue, strong margins, and positive analyst sentiment, but the elevated valuation and high beta introduce significant risk. The bull case is currently stronger, supported by concrete operational improvements and raised guidance, yet the stock's premium pricing leaves limited downside protection. The key tension is whether the market's growth expectations are justified; if revenue growth decelerates or margins compress, the stock could face multiple compression. Conversely, continued execution and successful Biocare integration could drive further upside.
Bullish
- Accelerating Revenue Growth: Q2 FY2026 revenue grew 10.01% YoY to $1.835B, up from 6.4% in Q1 FY2026 and 9.4% in Q4 FY2025, indicating strong momentum across all segments, particularly in biopharma and applied markets.
- Raised Guidance and Earnings Beat: The company beat Q2 expectations and raised its full-year profit forecast, leading to a stock surge. This reflects management confidence in sustained demand and operational efficiency.
- Strong Profitability Metrics: Gross margin expanded to 54.99% in Q2 FY2026, up from 51.9% in Q2 FY2025, and operating margin improved to 21.7%, demonstrating pricing power and cost discipline.
- Strategic Acquisition of Biocare Medical: The acquisition of Biocare Medical is expected to boost high-margin pathology sales, aligning with the company's focus on high-growth diagnostic niches and enhancing long-term revenue mix.
Bearish
- Elevated Valuation Metrics: Trailing PE of 31.89x and forward PE of 22.47x are above historical averages, and the PEG ratio of 9.44x suggests the market is pricing in aggressive growth that may not materialize, leaving little room for error.
- High Beta and Market Sensitivity: With a beta of 1.229, the stock is more volatile than the market, amplifying downside risk during broader sell-offs. The 1-year max drawdown of -29.87% highlights this vulnerability.
- Potential Overbought Conditions: Trading at 92.7% of its 52-week range, the stock may be approaching overbought levels, increasing the risk of a short-term pullback as profit-taking emerges.
- Integration Risks from Acquisitions: The Biocare Medical acquisition, while strategically sound, carries execution risks. If integration fails to deliver expected synergies, it could weigh on margins and distract management.
A Technical Analysis
Agilent's stock is in a clear uptrend, with a 1-year price change of +24.95% and currently trading at $148.53, which is 92.7% of its 52-week range (low $108.35, high $160.27). This positioning near the upper end of the range indicates strong momentum and investor confidence, though it also suggests the stock may be approaching overbought conditions. The 6-month change of +18.06% reinforces the sustained upward trajectory, with the stock recovering from a -29.87% max drawdown earlier in the period.
Beta
1.23
1.23x market volatility
Max Drawdown
-29.9%
Largest decline past year
52-Week Range
$108-$160
Price range past year
Annual Return
+25.6%
Cumulative gain past year
| Period | A Return | S&P 500 |
|---|---|---|
| 1m | +12.9% | +3.3% |
| 3m | +30.5% | +3.5% |
| 6m | +17.5% | +12.1% |
| 1y | +25.6% | +19.3% |
| ytd | +7.6% | +12.5% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
A Fundamental Analysis
Agilent's revenue growth is accelerating, with the most recent quarter (Q2 FY2026, ended April 30, 2026) reporting revenue of $1.835 billion, up 10.01% year-over-year, compared to 6.4% growth in the prior quarter (Q1 FY2026) and 9.4% in Q4 FY2025. The company's three segments—Life Sciences and Applied Markets ($732M), Agilent CrossLab ($759M), and Applied Markets ($344M)—all contributed to growth, with CrossLab showing the largest absolute revenue. This acceleration is driven by strong demand in biopharmaceutical and applied end markets, as well as recent acquisitions like Biocare Medical, which is expected to boost high-margin pathology sales.
Quarterly Revenue
$1.8B
2026-04
Revenue YoY Growth
+10.0%
YoY Comparison
Gross Margin
55.0%
Latest Quarter
Free Cash Flow
$1.3B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is A Overvalued?
Given Agilent's positive net income, the PE ratio is the primary valuation metric. The trailing PE is 31.89x, while the forward PE is 22.47x, indicating that the market expects significant earnings growth (approximately 42% increase) over the next year. This gap is consistent with the company's recent earnings beat and raised guidance, suggesting that the market is pricing in continued momentum. The PEG ratio of 9.44x, however, is elevated, implying that the current valuation may not fully justify the growth rate, but this could be due to cyclical factors in the diagnostics industry.
PE
31.9x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range 16x~44x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
23.4x
Enterprise Value Multiple
Investment Risk Disclosure
Financial risks include a debt-to-equity ratio of 0.50, which is manageable, but the company's reliance on continued growth to justify its valuation is a concern. The PEG ratio of 9.44x indicates that the stock is priced for high growth, and any shortfall could lead to a sharp de-rating. Additionally, free cash flow of $1.256B TTM is positive but may be strained by acquisition-related costs and integration expenses. The payout ratio of 21.6% and dividend yield of 0.68% are modest, but a cut in dividends could signal financial stress, though unlikely given current profitability.
FAQ
Key risks include: 1) Valuation risk: The stock trades at a forward PE of 22.47x, leaving little room for disappointment. 2) Operational risk: Integration of Biocare Medical may face execution challenges, potentially impacting margins. 3) Macro risk: With a beta of 1.229, the stock is sensitive to market downturns, and a hawkish Fed could compress multiples. 4) Competitive risk: Intense competition in life sciences tools could pressure pricing and market share. The most severe risk is a growth deceleration, which could lead to a 20-30% downside, as seen in the 52-week low of $108.35.
The 12-month forecast is moderately bullish. The base case (50% probability) sees the stock trading around $160, in line with the average analyst target. The bull case (35% probability) could push it to $185 if growth accelerates and margins expand. The bear case (15% probability) could see it fall to $135 if growth disappoints. The most likely scenario is continued growth at a decelerating pace, with the stock consolidating in the $150-$165 range. Key factors to watch are quarterly earnings and Biocare integration progress.
Agilent's trailing PE of 31.89x is above the market average, but the forward PE of 22.47x suggests the market expects significant earnings growth. The PEG ratio of 9.44x is elevated, indicating the stock may be overvalued relative to its growth rate. However, the company's consistent margin expansion and strategic acquisitions justify a premium. Compared to peers, Agilent trades at a similar or slightly higher multiple, reflecting its leadership position. Overall, the stock is fairly valued to slightly overvalued, with the market pricing in strong future growth.
Agilent is a good buy for investors seeking growth, given its accelerating revenue (10% YoY) and strong profitability (net margin 18.8%). The average analyst target of $160.11 implies a 7.8% upside, and the consensus is 'Buy'. However, the stock is not cheap at a forward PE of 22.47x, so it's best for those willing to pay a premium for quality. The main risk is a growth slowdown, which could lead to multiple compression. For long-term investors, the stock offers a compelling risk/reward, but short-term traders should be cautious of overbought conditions.
Agilent is better suited for long-term investment due to its strong fundamentals and growth prospects. The stock has a beta of 1.229, indicating higher volatility, which may deter short-term traders. The company's consistent revenue growth and margin expansion make it a solid long-term holding, with a suggested minimum holding period of 3-5 years. Short-term traders could profit from momentum, but the risk of overbought conditions and market volatility is higher. For long-term investors, the stock offers a good balance of growth and stability, with a modest dividend yield of 0.68%.